FDA OKs Satralizumab (Enspryng) for NMOSD

Satralizumab is a humanized monoclonal antibody that inhibits interleukin-6 receptor activity, believed to play a key role in the inflammation associated with NMOSD.
FDA Approvals

Full Story →